1. Pink Sheet
  2. >>Market Access

Biogen Value-Based Contract Links Patient-Reported Outcomes To MS Drug Reimbursement

 
• By Cathy Kelly

Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.

woman using a wheelchair in a park - Image
Biogen Contract With UPMC Will Focus On Worsening Physical DIsability

Biogen Inc. and the Pennsylvania-based UPMC Health Plan are breaking new ground with a value-based contract that links reimbursement to patient reported outcomes for the multiple sclerosis blockbuster Tecfidera (dimethyl fumerate) and Avonex (interferon beta-1a).

The contract will focus on outcomes related to worsening physical disability. Biogen and UPMC will also “continue to evaluate outcomes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

How Could MFN Pricing Impact Commercial Market?

 
• By Angela Maas

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By Cathy Kelly

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 
• By Francesca Bruce

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.